Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
9.260
-0.280 (-2.94%)
Streaming Delayed Price
Updated: 1:02 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
↗
December 03, 2024
Via
Benzinga
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
November 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
What's Next: Vir Biotechnology's Earnings Preview
↗
October 30, 2024
Via
Benzinga
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
↗
August 02, 2024
Via
Benzinga
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
November 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
November 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
↗
November 15, 2024
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.
Via
Benzinga
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
November 15, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
What You Missed On Wall Street This Past Friday
↗
November 03, 2024
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 31, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
October 17, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
October 15, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 03, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
September 10, 2024
From
Vir Biotechnology Inc.
Via
Business Wire
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
September 09, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
↗
August 01, 2024
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
↗
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
↗
July 04, 2024
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Via
InvestorPlace
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
June 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
↗
June 05, 2024
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.
Via
Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
June 05, 2024
Via
Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
↗
June 05, 2024
Via
Benzinga
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
June 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
